Do analysts prefer LFMD or MRAI?

LifeMD currently has a consensus target price of $9.14, indicating a potential upside of 145.12%. Given LifeMD's stronger consensus rating and higher probable upside, research analysts clearly believe LifeMD is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeMD 2 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.60 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, LFMD or MRAI?

LifeMD has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 0.93 $14.35M $0.05 74.60 Marpai $34.87M 1.66 -$28.75M -$0.87 N/A

Is LFMD or MRAI more profitable?

LifeMD has a net margin of 2.37% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Marpai -85.70% N/A -100.23%

Does the media prefer LFMD or MRAI?

In the previous week, LifeMD and LifeMD both had 1 articles in the media. LifeMD's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MRAI or XGN?

Exagen has a consensus price target of $9.00, suggesting a potential upside of 92.31%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89

Which has stronger earnings and valuation, MRAI or XGN?

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 1.66 -$28.75M -$0.87 N/A Exagen $66.57M 1.70 -$19.95M -$0.89 N/A

Is MRAI or XGN more profitable?

Exagen has a net margin of -29.49% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Exagen -29.49% -94.37% -28.96%

Does the media refer more to MRAI or XGN?

In the previous week, Exagen had 3 more articles in the media than Marpai. MarketBeat recorded 4 mentions for Exagen and 1 mentions for Marpai. Exagen's average media sentiment score of 0.26 beat Marpai's score of 0.00 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exagen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BNR or MRAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend MRAI or PARK?

Park Dental Partners has a consensus price target of $21.75, suggesting a potential upside of 17.50%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts plainly believe Park Dental Partners is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Park Dental Partners 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 2.75

Is MRAI or PARK more profitable?

Park Dental Partners has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Park Dental Partners N/A N/A N/A

Do analysts recommend MRAI or SERA?

Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 161.90%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts clearly believe Sera Prognostics is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sera Prognostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has higher valuation and earnings, MRAI or SERA?

Marpai has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 1.66 -$28.75M -$0.87 N/A Sera Prognostics $80K 1,027.95 -$31.93M -$0.65 N/A

Is MRAI or SERA more profitable?

Marpai has a net margin of -85.70% compared to Sera Prognostics' net margin of -56,385.97%. Marpai's return on equity of 0.00% beat Sera Prognostics' return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Sera Prognostics -56,385.97% -41.02% -30.95%

Does the media refer more to MRAI or SERA?

In the previous week, Sera Prognostics had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Sera Prognostics and 1 mentions for Marpai. Marpai's average media sentiment score of 0.00 equaled Sera Prognostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Marpai (MRAI) Competitors

$2.15 -0.08 (-3.59%)

As of 03:56 PM Eastern

Compare

MRAI vs. LFMD, XGN, BNR, PARK, and SERA

Should you buy Marpai stock or one of its competitors? MarketBeat compares Marpai with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marpai include LifeMD (LFMD), Exagen (XGN), Burning Rock Biotech (BNR), Park Dental Partners (PARK), and Sera Prognostics (SERA).

How does Marpai compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, LifeMD and LifeMD both had 1 articles in the media. LifeMD's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LifeMD has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Marpai has a beta of 4.92, indicating that its share price is 392% more volatile than the broader market.

LifeMD has a net margin of 2.37% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Marpai	-85.70%	N/A	-100.23%

LifeMD currently has a consensus target price of $9.14, indicating a potential upside of 145.12%. Given LifeMD's stronger consensus rating and higher probable upside, research analysts clearly believe LifeMD is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

LifeMD has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.93	$14.35M	$0.05	74.60
Marpai	$34.87M	1.66	-$28.75M	-$0.87	N/A

Summary

LifeMD beats Marpai on 9 of the 14 factors compared between the two stocks.

How does Marpai compare to Exagen?

Marpai (NASDAQ:MRAI) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.66	-$28.75M	-$0.87	N/A
Exagen	$66.57M	1.70	-$19.95M	-$0.89	N/A

Exagen has a net margin of -29.49% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Exagen	-29.49%	-94.37%	-28.96%

49.8% of Marpai shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 10.4% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Marpai has a beta of 4.92, meaning that its share price is 392% more volatile than the broader market. Comparatively, Exagen has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

In the previous week, Exagen had 3 more articles in the media than Marpai. MarketBeat recorded 4 mentions for Exagen and 1 mentions for Marpai. Exagen's average media sentiment score of 0.26 beat Marpai's score of 0.00 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exagen has a consensus price target of $9.00, suggesting a potential upside of 92.31%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Exagen beats Marpai on 12 of the 17 factors compared between the two stocks.

How does Marpai compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Marpai had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 1 mentions for Marpai and 0 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
Marpai	Neutral

Burning Rock Biotech has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Marpai has a beta of 4.92, indicating that its stock price is 392% more volatile than the broader market.

Burning Rock Biotech has higher revenue and earnings than Marpai. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.21	-$7.92M	-$0.82	N/A
Marpai	$34.87M	1.66	-$28.75M	-$0.87	N/A

Burning Rock Biotech has a net margin of -11.57% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Marpai	-85.70%	N/A	-100.23%

Summary

Marpai beats Burning Rock Biotech on 7 of the 13 factors compared between the two stocks.

How does Marpai compare to Park Dental Partners?

Marpai (NASDAQ:MRAI) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Park Dental Partners has a consensus price target of $21.75, suggesting a potential upside of 17.50%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts plainly believe Park Dental Partners is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Park Dental Partners has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.66	-$28.75M	-$0.87	N/A
Park Dental Partners	$244.49M	0.34	-$360K	$0.74	25.01

Park Dental Partners has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Park Dental Partners	N/A	N/A	N/A

49.8% of Marpai shares are held by institutional investors. 46.1% of Marpai shares are held by company insiders. Comparatively, 10.6% of Park Dental Partners shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Marpai had 1 more articles in the media than Park Dental Partners. MarketBeat recorded 1 mentions for Marpai and 0 mentions for Park Dental Partners. Marpai's average media sentiment score of 0.00 equaled Park Dental Partners'average media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
Park Dental Partners	Neutral

Summary

Park Dental Partners beats Marpai on 9 of the 13 factors compared between the two stocks.

How does Marpai compare to Sera Prognostics?

Marpai (NASDAQ:MRAI) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

49.8% of Marpai shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Marpai has a net margin of -85.70% compared to Sera Prognostics' net margin of -56,385.97%. Marpai's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 161.90%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts clearly believe Sera Prognostics is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Marpai has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	1.66	-$28.75M	-$0.87	N/A
Sera Prognostics	$80K	1,027.95	-$31.93M	-$0.65	N/A

In the previous week, Sera Prognostics had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Sera Prognostics and 1 mentions for Marpai. Marpai's average media sentiment score of 0.00 equaled Sera Prognostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Marpai has a beta of 4.92, indicating that its share price is 392% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Summary

Sera Prognostics beats Marpai on 9 of the 16 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$57.78M	$9.93B	$6.86B	$12.45B
Dividend Yield	N/A	2.54%	2.60%	10.03%
P/E Ratio	-0.81	25.38	280.72	24.99
Price / Sales	1.66	4.92	588.04	90.94
Price / Cash	N/A	26.44	28.64	34.82
Price / Book	-1.25	5.22	11.02	6.21
Net Income	-$28.75M	$312.25M	$3.48B	$347.49M
7 Day Performance	-4.02%	-0.20%	0.56%	0.89%
1 Month Performance	206.27%	-0.89%	-4.14%	-3.60%
1 Year Performance	82.20%	27.08%	63.23%	20.46%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$2.15 -3.6%	N/A	+89.0%	$57.78M	$34.87M	N/A	150
LFMD LifeMD	2.2051 of 5 stars	$3.64 -5.2%	$9.14 +151.2%	-64.8%	$185.71M	$194.05M	72.81	230	Upcoming Earnings
XGN Exagen	2.9143 of 5 stars	$4.35 -2.2%	$9.00 +106.9%	-47.5%	$107.51M	$66.57M	N/A	220	News Coverage Upcoming Earnings
BNR Burning Rock Biotech	0.638 of 5 stars	$8.82 -4.0%	N/A	+54.9%	$96.66M	$77.16M	N/A	1,390	Analyst Downgrade
PARK Park Dental Partners	4.1228 of 5 stars	$17.66 -3.6%	$21.75 +23.2%	N/A	$82.72M	$248.15M	23.86	1,212	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors

MRAI vs. LFMD, XGN, BNR, PARK, and SERA

How does Marpai compare to LifeMD?

Summary

How does Marpai compare to Exagen?

Summary

How does Marpai compare to Burning Rock Biotech?

Summary

How does Marpai compare to Park Dental Partners?

Summary

How does Marpai compare to Sera Prognostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marpai (MRAI) Competitors

MRAI vs. LFMD, XGN, BNR, PARK, and SERA

How does Marpai compare to LifeMD?

Does the media prefer LFMD or MRAI?

Do insiders & institutionals have more ownership in LFMD or MRAI?

Which has more volatility & risk, LFMD or MRAI?

Is LFMD or MRAI more profitable?

Do analysts prefer LFMD or MRAI?

Which has better earnings & valuation, LFMD or MRAI?

Summary

How does Marpai compare to Exagen?

Which has stronger earnings and valuation, MRAI or XGN?

Is MRAI or XGN more profitable?

Do institutionals and insiders hold more shares of MRAI or XGN?

Which has more risk and volatility, MRAI or XGN?

Does the media refer more to MRAI or XGN?

Do analysts prefer MRAI or XGN?

Summary

How does Marpai compare to Burning Rock Biotech?

Do insiders and institutionals believe in BNR or MRAI?

Do analysts prefer BNR or MRAI?

Does the media favor BNR or MRAI?

Which has more volatility and risk, BNR or MRAI?

Which has preferable earnings & valuation, BNR or MRAI?

Is BNR or MRAI more profitable?

Summary

How does Marpai compare to Park Dental Partners?

Do analysts recommend MRAI or PARK?

Which has better earnings and valuation, MRAI or PARK?

Is MRAI or PARK more profitable?

Do insiders & institutionals hold more shares of MRAI or PARK?

Does the media favor MRAI or PARK?

Summary

How does Marpai compare to Sera Prognostics?

Do insiders and institutionals hold more shares of MRAI or SERA?

Is MRAI or SERA more profitable?

Do analysts recommend MRAI or SERA?

Which has higher valuation and earnings, MRAI or SERA?

Does the media refer more to MRAI or SERA?

Which has more risk & volatility, MRAI or SERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools